How Will Fujifilm (FUJIY) Stock Be Boosted By Ebola Drug Approval?

NEW YORK (TheStreet) -- Shares of Fujifilm Holdings Corp. (FUJIY) are up 8.83% to $30.92 after it was reported that U.S. government researchers are working to get an experimental flu drug from the Japan-based company quickly approved to treat Ebola, as the death toll in West Africa increases, Bloomberg reports..

Fujifilm's U.S. partner MediVector Inc. in Boston is in talks with the FDA to submit an application to use the drug in humans for Ebola, according to the Defense Department. If successful, the treatment drug would be one of the first allowed by U.S. regulators to fight the disease in humans, Bloomberg said.

The DOD prioritized the completion of a study that tests the drug called favipiravir in Ebola-infected monkeys. The drug can be fast-tracked through the regulatory review process after the studies are complete, and preliminary monkey data are expected in mid-September.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

FUJIY ChartFUJIY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Sony Patent Infringement Claim Results in Investigation of FujiFilm Imports

Sony Patent Infringement Claim Will Launch Investigation of FujiFilm Imports

Here's What We Can Learn About Market Timing From the Trump Rally

Will Fujifilm (FUJIY) Stock Be Affected Today by This Analyst Action?

FUJIFILM (FUJIY) Stock Higher Today on Kalon Purchase